Altogether, the evidence shows that FXR agonism within the liver could prevent de novo lipogenesis, inflammation, and fibrosis in the frame of NAFLD/MASLD physiopathology [46,47,48]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.